Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055397 | 0.91 | KDM4A (0.51) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL184953 | 0.88 | GLS (0.54) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL27113190 | 0.87 | CA1 (0.47) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL99337 | 0.87 | TPSAB1 (0.56) | KDM4AL3MBTL1NAMPTCA1CA2 | |
| SCHEMBL22702229 | 0.87 | KDM4A (0.46) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| Hydrochloric Acid SCHEMBL31609012 | 0.86 | GLS (0.53) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL22702218 | 0.85 | KDM4A (0.47) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL14877950 | 0.85 | KDM4A (0.47) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL15874006 | 0.84 | KDM4A (0.42) | KDM4AL3MBTL1GLSNAMPTCA1 | |
| SCHEMBL1866534 | 0.84 | CA2 (0.49) | NAMPTCA1CA2GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | KDM4A 4030/4885L3MBTL1 2883/4885GLS 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.